VivoSeq
Cardiovascular

ST Elevation Myocardial Infarction

37

Pipeline Programs↗

2

Active Trials↗

25

Companies Involved↗

ST Elevation Myocardial Infarction is a moderately active landscape with 37 programs across 25 companies. The most active players are Bristol-Myers Squibb, KAI Pharmaceuticals, Watson Pharmaceuticals. 14 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

6/100

Mech. Concentration

9/100

Completion Rate

80/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1K

KAI Pharmaceuticals

1 program

Phase 2W

Watson Pharmaceuticals

1 program

Phase 2H

Hope Pharmaceuticals

1 program

Phase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 2Sanofi logo

Sanofi

4 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

34 of 40 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody38%Protein / enzyme25%Peptide13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Withdrawn2 · 11%
Unknown status2 · 11%
Terminated1 · 5%
Recruiting1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
Recruiting·AAO GENERIUM·Phase 3·NCT05601999·244 enrolled
CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)
Not yet recruiting·OOdense University Hospital·Preclinical·NCT07646977·100 enrolled
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Completed·HHospital do Coracao·Phase 3·NCT02298088·3,799 enrolled
Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)
Completed·YYonsei University·Phase 4·NCT00808717·170 enrolled
Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction
Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT05247424·600 enrolled
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Completed·GSK logoGSK·Phase 3·NCT00426751·429 enrolled
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Completed·Sanofi logoSanofi·Phase 3·NCT01076764·13,220 enrolled
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT03578809·593 enrolled
Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction
Completed·—·Phase 4·NCT00986050·907 enrolled
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Completed·KKAI Pharmaceuticals·Phase 2·NCT00785954·1,180 enrolled
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
Completed·UUniversity of Patras·Phase 4·NCT01950416·56 enrolled
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study
Completed·HHospices Civils de Lyon·Phase 3·NCT02934217·868 enrolled
Distal Versus Conventional Transradial Artery Access for Coronary Catheterization in Patients With ST-elevation Myocardial Infraction (STEMI): The DR-STEMI Trial
Completed·UUniversity Hospital of Patras·Preclinical·NCT05605288·554 enrolled
Intracoronary Administration of Epinephrine and Verapamil in the Refractory No-reflow Phenomenon in Patients With Acute Myocardial Infarction: The EPIVER Randomized Controlled Trial
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Preclinical·NCT04573751·104 enrolled
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Terminated·Sanofi logoSanofi·Phase 3·NCT00670228·34 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)